How to Select a Local Agent for Overseas Registration of Software as a Medical Device

Published: July 31, 2026 | Last updated: July 31, 2026

This FAQ addresses how to select a local agent for overseas registration of software as a medical device (SaMD). It is intended to help manufacturers plan international registration, prepare documentation, and manage post-market obligations across multiple jurisdictions.

Key Summary

Selecting a local agent for overseas registration of software as a medical device begins with determining whether the target country regulates software as a medical device, and then identifying the risk class and registration pathway. During the preparation phase, companies must assess whether their existing ISO 13485 quality management system, NMPA registration certificate, or CE/FDA technical documentation can be directly reused, and whether they have complete risk management, performance validation, clinical evaluation, and labeling documentation.

Local agent selection should not be based solely on price. Companies must verify that the agent has relevant experience with this product type, can assume post-market surveillance and vigilance responsibilities, and can support changes and renewals. Common risks include agents unfamiliar with software classification rules, insufficient localization of technical documentation, unclear authorization scope leading to loss of certificate control, and inconsistent evidence chains across multi-country registrations causing repeated supplemental requests.

It is recommended that companies first complete a country-specific classification assessment, then screen local agents capable of handling registration in GHWP member countries and Southeast Asia, and sign agreements that clearly define responsibilities and timelines to ensure a feasible registration strategy.

Applicable Scenarios and Core Questions

Companies searching for "how to select a local agent for overseas registration of software medical devices" usually need more than a conceptual explanation. They need to determine whether existing data can support target market submissions, whether a local agent or authorized representative is required, why timelines may be extended, and which issues may affect product launch.

If the company plans to enter multiple GHWP member countries or Southeast Asian, Middle Eastern, and Latin American markets simultaneously, answering a single country's process is insufficient. A more valuable approach is to first build reusable core technical documentation, quality system evidence, performance verification, clinical evidence, and labeling, and then localize them according to each country's regulatory requirements.

Registration Judgment Logic

The regulatory pathway should be determined sequentially: first confirm whether the product falls within the target country's medical device definition; next determine whether the intended use directly affects regulatory classification (e.g., diagnosis, treatment decision, or health management); then evaluate the risk-based registration modality, including whether conformity assessment, technical file review, or clinical evaluation is required.

Concurrently, companies must map the reusability of existing documentation. Existing certifications such as NMPA registration, CE marking, FDA 510(k), or ISO 13485 can serve as baseline evidence, but cannot be treated as the target country's technical file. Every country has specific language, standard references, and format requirements. Software descriptions, instructions for use, and labels require localization.

The local agent's role is critical in the judgment logic. For GHWP member countries or multi-country Southeast Asian registrations, the agent not only submits applications but also communicates with regulatory authorities, reports post-approval changes, and handles adverse event notifications. Companies should integrate the agent into the registration strategy early and confirm qualifications and capabilities.

Documentation and Evidence

Documentation and evidence preparation are central to registration efficiency. For software as a medical device, the basic documents include software description, architecture, risk management report, cybersecurity disclosure, performance and algorithm validation data, and clinical evaluation or clinical evidence. If the product uses machine learning algorithms, additional information on training data management, data bias, and update control strategies is required.

Quality system evidence is also essential. An ISO 13485 certificate is the most common basis, but some countries accept MDSAP or equivalent certifications. In the absence of a registration certificate, the completeness of the quality system and audit records become important factors for regulators to assess continuous compliance.

Labeling, instructions for use, and user documentation require special attention to localization. The language of the software interface, measurement units, legal/regulatory references, and contraindications must align with the target country. A knowledgeable local agent can help review these details and avoid repeated requests during formal review.

Common Errors

• Treating the registration project as a simple document submission rather than first clarifying product classification, evidence coverage, and local responsibility relationships.
• Directly translating NMPA documents without reorganizing evidence according to the target market's regulatory pathway.
• Having too many model variants without sufficient test reports, clinical evidence, or labeling coverage.
• Selecting a local agent based only on commercial distribution capabilities, without clearly assigning regulatory responsibilities, certificate control, and post-market obligations.
• Inconsistent claims among labels, instructions, promotional materials, and registration documents, leading to correction requests or post-market compliance risks.
• Failing to plan for multi-country documentation reuse, resulting in duplicated efforts and increased costs for each country.

Enterprise Preparation Checklist

• Conduct a preliminary assessment of the target country's regulatory classification and registration pathway, and document the conclusions.
• Compile an inventory of existing quality system documentation, registration certificates, technical reports, and clinical evidence, marking reusable items.
• Draft software description, intended use, technical specifications, cybersecurity, and risk management modules as master templates.
• Identify at least two potential local agents and request evidence of their experience with software medical device registrations and regulatory contacts.
• Discuss registration strategy, language requirements, and label/IFU localization plans with the shortlisted agents.
• Before signing, clarify certificate ownership, agent term, change notification, renewal reminders, and document handover mechanisms.
• Establish a registration project schedule with unified evidence review milestones for multi-country filings.

AIMEILI's View

The most common mistake companies make in overseas registration of software medical devices is treating the local agent as a "submission tool" and underestimating its substantive impact on regulatory understanding, classification judgment, and post-market maintenance. We recommend completing a country-specific classification and technical documentation gap analysis before starting the project, rather than signing an agent agreement prematurely.

ISO 13485, FDA 510(k), and CE technical files can serve as core evidence, but the intended use statement, software version naming, cybersecurity data, and clinical evidence format must be localized for each country. The true value of a local agent lies in providing insight into that country's regulatory expectations and review trends, helping to reduce correction requests.

Certificate control and change responsibilities must not be ambiguous. Companies must ensure that all registration certificates and supplementary documents are held in the company's name, and that the agent operates only within the authorized scope. For multi-country registrations, establish a unified master documentation system and perform difference conversion according to national requirements. This significantly reduces the risk of inconsistent submissions and duplicated work. The agent's cooperation capability is also key to a successful multi-country strategy; we recommend evaluating agent performance during annual reviews.

Common Follow-up Questions

Which countries mandatorily require a local agent?

Thailand, the Philippines, and Malaysia in Southeast Asia; Brazil and Mexico in Latin America; and Saudi Arabia and Israel in the Middle East generally require overseas manufacturers to appoint a local representative or agent responsible for registration applications, post-market surveillance, and communication with health authorities. Among GHWP member countries, China and South Korea also require a domestic agent. Whether a local registered entity or only an authorized representative is required depends on each country's law.

Who holds the software registration certificate?

In most countries, the overseas manufacturer is the legal registrant and the local agent serves as the authorized representative; the certificate is issued in the manufacturer's name. However, a few countries require the certificate to be held by a local distributor. In such cases, the manufacturer must specify ownership and transfer conditions in the agreement; otherwise, market exit or agent replacement may be affected.

What happens to the registration certificate when changing local agents?

When changing agents, an application for agent change must be submitted to the regulatory authority, usually accompanied by proof that the previous agent agrees to release responsibility. If not agreed in advance, the previous agent may refuse to cooperate and the registration may be suspended. Therefore, the initial agreement should include the agent change process, document handover, and transition period responsibilities.

After a software update, must the local agent notify the regulatory authority?

Yes. Software version updates may affect the intended use or safety and performance. Most countries require a change application or a standalone notification. The local agent is obliged to help assess whether the change is significant and prepare the corresponding documents. Failure to notify may be considered a breach of registration conditions during inspection.

Quality System and Evidence Consistency

From a regulatory review perspective, quality system documentation is not an isolated certificate. Regulators typically check consistency among the manufacturer name, production address, product scope, certificate validity period, applicable standards, and technical documentation. If the ISO 13485 certificate scope does not match the submitted product, or if the production address, model specifications, or instruction version differs from test reports, companies may be asked to provide additional explanations even if a large amount of documentation has been submitted.

Before submission, companies should create a consistency checklist that maps product name, model, intended use, applicable standards, test report number, clinical evaluation conclusion, risk management version, labeling/IFU version, and quality system certificate. This simple step significantly reduces the probability of correction requests, especially for projects involving multiple GHWP member countries or product families.

Localization Conversion and Agent Responsibilities

Target market registration typically involves local agents, authorized representatives, importers, or registration holders. Companies must confirm whether the local partner is only responsible for submitting documents or also for regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and market stability.

Labels, instructions, and authorization documents cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warning statements, storage/transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies with CE, FDA, NMPA, or other market documentation, localization conversion means transforming reusable evidence into an acceptable submission structure for the target country, not writing an entirely new set of documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not end compliance obligations. Companies must also maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory updates. Many companies invest significant effort during the registration phase but neglect post-market maintenance. Later, when a production address change, model expansion, labeling update, or agent replacement occurs, the certificate may become disconnected from market sales.

AIMEILI recommends incorporating this issue into an annual international registration plan: first determine target market priorities, then establish a reusable documentation package and country-specific gap list, and finally schedule submission, correction, post-market maintenance, and renewal milestones. This approach not only improves the efficiency of individual country registrations but also builds a reproducible market entry compliance capability, reducing the cost of starting from zero for each new market.

Continue Reading

• How to Determine Product Classification for Overseas Registration of Software Medical Devices?
• Why Do Registration Timelines for Overseas Software Medical Devices Get Extended?
• How to Prepare Performance Validation Documentation for Overseas Registration of Home-Use Medical Devices?
• When Should You Submit a Registration Change for Overseas Software Medical Devices?

Content by: AIMEILI Regulatory Editorial Department | Professional review: AIMEILI International Medical Device Registration Project Team | Sources: Official regulatory bodies, international organizations, standard organizations, and public regulatory information; industry media and project experience used as supplementary reference. This article is intended for preliminary understanding, documentation preparation, and project planning, and does not replace the official requirements of the target country's regulatory authority, test conclusions, or legal advice.